동물 의료 수탁 제조 및 연구 시장 예측(-2031년) : 서비스(디스커버리, API 개발, 규제 대응, 컨설팅, 포장 및 라벨링), 제품(API, Fill-Finish, 의료기기), 동물 유형별(반려동물, 가축)

The veterinary contract manufacturing & research market is expected to grow from USD 6.38 billion in 2026 to USD 9.24 billion by 2031, at a CAGR of 7.7%. The market growth is driven by several key factors shaping the future of veterinary drug development, biologics manufacturing, and precision animal health.

A major driver of this growth is the increasing demand for outsourced development and manufacturing services as animal health companies seek to accelerate product pipelines, reduce internal costs, and access specialized expertise for complex therapeutics such as biologics, vaccines, and advanced formulations. As the veterinary industry shifts toward more targeted, data-driven treatment approaches, the need for high-quality research, analytical testing, and GMP-compliant production is rapidly rising. Additionally, the growing burden of chronic, infectious, and zoonotic diseases in both companion and livestock animals is driving demand for faster and more efficient research and development (R&D) processes. CDMOs and CROs play a critical role in meeting this need by providing scalable manufacturing, high-throughput screening, and advanced study capabilities. The ongoing trend toward modernization in veterinary healthcare, including the adoption of real-time monitoring tools, digital workflows, and improved clinical trial management, further strengthens reliance on specialized outsourcing partners.

Technological advancements, including the integration of AI for predictive modeling, automation in bioprocessing, and the development of enhanced analytical platforms, also drive market growth. These innovations enhance accuracy, shorten development timelines, and expand the applications of outsourced services across preclinical, clinical, and commercial phases. Overall, rising industry demands, advancements in technology, and the growing shift toward specialized and outsourced expertise are driving strong and sustained growth in the veterinary contract manufacturing & research market.

"By animal type, the companion animals segment is projected to grow at the highest CAGR during the forecast period."

The software & services segment is expected to see the highest growth in the veterinary contract manufacturing & research market, due to rising pet ownership, increasing spending on advanced treatments, and growing demand for innovative therapeutics for dogs and cats. Conditions such as cancer, obesity, allergies, and chronic diseases are becoming more prevalent in pets, driving the need for new drugs, biologics, and specialty formulations. Pet owners' willingness to invest in premium care, coupled with the humanization of pets and expanding insurance coverage, is encouraging animal health companies to develop more complex products-leading to greater outsourcing of R&D, manufacturing, and clinical studies to CDMOs and CROs.

"By end user, the multinational animal-health companies segment accounted for the largest market share in 2024."

In 2024, the veterinary clinics segment dominated the veterinary contract manufacturing & research market because they manage extensive product pipelines, operate globally regulated supply chains, and consistently invest in developing advanced therapeutics, vaccines, and diagnostics. Their broad portfolios and high production volumes create a strong need for specialized outsourcing partners to support formulation, scale-up, analytical testing, and clinical research. Additionally, these companies increasingly rely on CDMOs and CROs to accelerate time-to-market, expand manufacturing capacity, and access cutting-edge technologies, making them the primary contributors to overall market demand.

"The Asia Pacific region is projected to witness the highest growth rate during the forecast period."

The Asia Pacific is expected to experience the highest growth in the veterinary contract manufacturing & research market, driven by rising livestock production, increasing pet ownership, and growing investment in animal health infrastructure across countries such as China, India, and Southeast Asia. The region is witnessing rapid expansion of veterinary pharmaceutical manufacturing, greater adoption of advanced biologics and diagnostics, and stronger government support for disease control and vaccination programs. Additionally, lower operational costs, improving regulatory frameworks, and the emergence of local CDMOs and CROs are attracting global animal health companies to outsource more research and manufacturing to APAC, driving its accelerated growth.

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%)
• By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%)
• By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

• By End User: Multinational animal-health companies (59%), mid-sized / specialty animal-health firms (26%), and start-ups & veterinary biotech firms (15%)
• By Designation: R&D directors/heads of research (47%), product development & innovation managers (22%), regulatory affairs managers/directors (15%), and others (16%)
• By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)

Research Coverage

The market study covers the veterinary contract manufacturing & research market in various segments. It aims to estimate the market size and growth potential of this market by service, product type, animal type, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their products and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report can help established companies and newer or smaller firms understand market trends, enabling them to capture a larger market share. Firms that acquire the report can implement one or more of the five strategies outlined below.

This report provides insights into the following points:

• Analysis of key drivers (growth in animal health spending, increasing complexity of veterinary biologics and the increasing regulatory burden for GMP, biosecurity & environmental compliance.), restraints (limited specialized infrastructure and long approval timelines & regulatory diversity globally), opportunities (geographic expansion into emerging markets, digital CRO services), and challenges (difficulty in clinical trial recruitment and difficulty in scaling sterile/biologics capacity quickly) influencing the growth of the veterinary contract manufacturing & research market
• Product Development/Innovation: Detailed insights on upcoming technologies and service launches in the veterinary contract manufacturing & research market
• Market Development: Comprehensive information about lucrative emerging markets; the report analyzes the markets for various types of veterinary CDMO & CRO services across regions
• Market Diversification: Exhaustive information about services, untapped regions, recent developments, and investments in the veterinary contract manufacturing & research market
• Competitive Assessment: In-depth assessment of market shares, strategies, services, distribution networks, and manufacturing capabilities of the leading players in the veterinary contract manufacturing & research market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 LIMITATIONS

2 EXECUTIVE SUMMARY

3 PREMIUM INSIGHTS

• 3.1 VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET OVERVIEW
• 3.2 ASIA PACIFIC: VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET, BY SERVICE & COUNTRY (2025)
• 3.3 VETERINARY CROS MARKET: REGIONAL MIX
• 3.4 VETERINARY CDMOS MARKET: REGIONAL MIX
• 3.5 VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.6 VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET: DEVELOPED VS. EMERGING ECONOMIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growth in animal health spending
    • 4.2.1.2 Increasing complexity of veterinary biologics
    • 4.2.1.3 Rising regulatory requirements for GMP, biosecurity, and environmental compliance
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Limited specialized infrastructure
    • 4.2.2.2 Long approval timelines & regulatory diversity globally
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Geographic expansion into emerging markets
    • 4.2.3.2 Digital CRO services
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Challenges in clinical trial recruitment
    • 4.2.4.2 Difficulty in scaling sterile/biologics capacity quickly
• 4.3 UNMET NEEDS & WHITE SPACES
  • 4.3.1 UNMET NEEDS IN VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
  • 4.5.1 UNMET NEEDS IN VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND OF API & FILL-FINISH PHARMACEUTICALS & BIOLOGICS, BY KEY PLAYER, 2023-2025
  • 5.6.2 AVERAGE SELLING PRICE TREND OF API & FILL-FINISH PHARMACEUTICALS & BIOLOGICS, BY REGION, 2023-2025
    • 5.6.2.1 Average selling price trend of small-molecule pharmaceuticals for API/drug substance manufacturing, by region, 2023-2025
    • 5.6.2.2 Average selling price trend of small-molecule pharmaceuticals for fill-finish/drug product manufacturing, by region, 2023-2025
    • 5.6.2.3 Average selling price trend of animal health biologics & vaccines for API/drug substance manufacturing, by region, 2023-2025
    • 5.6.2.4 Average selling price trend of animal health biologics & vaccines for fill-finish/drug product manufacturing, by region, 2023-2025
• 5.7 KEY CONFERENCES & EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT & FUNDING SCENARIO
• 5.10 SUCCESS STORIES & REAL-WORLD APPLICATIONS
  • 5.10.1 END-TO-END CDMO SUPPORT FOR ANIMAL HEALTH LATERAL FLOW DIAGNOSTICS
  • 5.10.2 END-TO-END CDMO SUPPORT FOR FIRST-IN-CLASS VETERINARY MONOCLONAL ANTIBODY (MAB)
  • 5.10.3 END-TO-END BIOLOGICS OPTIMIZATION FOR CANINE ANTIBODY PROGRAMS

6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1.1 High-throughput in vitro & in vivo screening platforms
    • 6.1.1.2 AI/ML platforms for drug discovery
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Laboratory automation, robotics, and smart QC systems
    • 6.1.2.2 Stability, cold chain, and packaging optimization technologies
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Digital therapeutics & software-as-a-medical-device (SaMD)
    • 6.1.3.2 Precision livestock technologies
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
  • 6.2.1 NEAR TERM (2025-2027)
  • 6.2.2 MID TERM (2028-2030)
  • 6.2.3 LONG TERM (2030+)
• 6.3 PATENT ANALYSIS
  • 6.3.1 PATENT PUBLICATION TRENDS FOR VETERINARY PHARMACEUTICALS
  • 6.3.2 JURISDICTION & TOP APPLICANT ANALYSIS
• 6.4 FUTURE APPLICATIONS
  • 6.4.1 ADVANCED BIOLOGICS & VACCINE MANUFACTURING PLATFORMS
  • 6.4.2 DIGITALIZED, DATA-RICH CLINICAL DEVELOPMENT USING AI, REMOTE MONITORING, AND REAL-WORLD DATA
  • 6.4.3 GLOBALIZED, REGULATORY-READY DEVELOPMENT WITH HARMONIZED QUALITY & MANUFACTURING SYSTEMS
  • 6.4.4 INNOVATIVE FORMULATION TECHNOLOGIES FOR LONG-ACTING, SPECIES-TAILORED, AND DIFFICULT-TO-DELIVER PRODUCTS
• 6.5 IMPACT OF AI/GENERATIVE AI ON VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET
  • 6.5.1 INTRODUCTION
  • 6.5.2 MARKET POTENTIAL IN VETERINARY CONTRACT MANUFACTURING & RESEARCH ECOSYSTEM
  • 6.5.3 AI USE CASES
  • 6.5.4 KEY COMPANIES IMPLEMENTING AI IN VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY ANALYSIS
  • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR VETERINARY PRODUCTS
  • 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
  • 7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 KEY STAKEHOLDERS & BUYING CRITERIA
  • 8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.1.2 BUYING CRITERIA
• 8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
  • 8.2.1 DECISION-MAKING PROCESS
  • 8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
  • 8.2.4 MARKET PROFITABILITY

9 VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET, BY SERVICE

• 9.1 INTRODUCTION
• 9.2 CRO SERVICES
  • 9.2.1 DISCOVERY & PRE-CLINICAL STUDIES
    • 9.2.1.1 Growing use of discovery & pre-clinical studies to accelerate veterinary drug pipeline initiation
  • 9.2.2 VETERINARY CLINICAL TRIALS
    • 9.2.2.1 Growing dependence on veterinary clinical trials to validate safety and efficacy for regulatory approvals to boost market
  • 9.2.3 ANALYTICAL & BIOANALYTICAL SERVICES AND QUALITY ASSURANCE
    • 9.2.3.1 Rising adoption of analytical & bioanalytical services to ensure high-quality, compliant veterinary products to fuel growth
  • 9.2.4 REGULATORY AFFAIRS & CONSULTING
    • 9.2.4.1 Increasing need for regulatory affairs & consulting to navigate complex global veterinary approval pathways to support growth
• 9.3 CDMO SERVICES
  • 9.3.1 PROCESS API & FORMULATION DEVELOPMENT
    • 9.3.1.1 Growing focus on process API & formulation development to optimize veterinary product performance to drive growth
  • 9.3.2 MANUFACTURING
    • 9.3.2.1 Increasing outsourcing of manufacturing to scale production of veterinary drugs and biologics
  • 9.3.3 PACKAGING & LABELING
    • 9.3.3.1 Rising dependence on packaging & labeling services to ensure regulatory-compliant product delivery to propel market
  • 9.3.4 QUALITY/STABILITY & POST-MARKET SUPPORT
    • 9.3.4.1 Expanding use of quality, stability, and post-market support to maintain lifecycle product compliance to boost market

10 VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET, BY PRODUCT TYPE

• 10.1 INTRODUCTION
• 10.2 MEDICINES
  • 10.2.1 SMALL-MOLECULE PHARMACEUTICALS
    • 10.2.1.1 API/Drug substance manufacturing
      • 10.2.1.1.1 Growing focus on API manufacturing to support market growth
      • 10.2.1.1.2 Global volume analysis of small-molecule pharmaceuticals market for API/drug substance manufacturing, by type, 2024-2031 (metric tons)
    • 10.2.1.2 Fill-finish/drug product manufacturing
      • 10.2.1.2.1 Increasing demand for fill-finish operations to fuel market growth
      • 10.2.1.2.2 Global volume analysis of small-molecule pharmaceuticals market for fill-finish/drug product manufacturing, by type, 2024-2031 (ten thousand units)
  • 10.2.2 ANIMAL HEALTH BIOLOGICS & VACCINES
    • 10.2.2.1 API/Drug substance manufacturing
      • 10.2.2.1.1 Rising demand for API/drug substance manufacturing to drive growth
      • 10.2.2.1.2 Global volume analysis of animal health biologics & vaccines for API/drug substance manufacturing, by type, 2024-2031 (metric tons)
    • 10.2.2.2 Fill-finish/drug product manufacturing
      • 10.2.2.2.1 Rising dependence on fill-finish capabilities to fuel growth
      • 10.2.2.2.2 Global volume analysis of animal health biologics & vaccines market for fill-finish/drug product manufacturing, by type, 2024-2031 (thousand units)
  • 10.2.3 MEDICATED FEED & SUPPLEMENTS
    • 10.2.3.1 Rising use of medicated feed & supplements to enhance livestock health and productivity
• 10.3 MEDICAL DEVICES
  • 10.3.1 DIAGNOSTICS
    • 10.3.1.1 Growing adoption of veterinary diagnostics to drive market growth
  • 10.3.2 MONITORING SYSTEMS
    • 10.3.2.1 Expanding utilization of monitoring systems to improve real-time animal health management to fuel growth
  • 10.3.3 IMPLANTS
    • 10.3.3.1 Increasing use of veterinary implants to support long-term treatment and orthopedic care to drive growth

11 VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET, BY ANIMAL TYPE

• 11.1 INTRODUCTION
• 11.2 COMPANION ANIMALS
  • 11.2.1 DOGS
    • 11.2.1.1 High adoption rates of dogs to drive market growth
  • 11.2.2 CATS
    • 11.2.2.1 Rising disease prevalence among cats to drive market
  • 11.2.3 HORSES
    • 11.2.3.1 Growing equine population to support market growth
  • 11.2.4 OTHER COMPANION ANIMALS
• 11.3 LIVESTOCK ANIMALS
  • 11.3.1 CATTLE
    • 11.3.1.1 Growing consumption of meat to drive market
  • 11.3.2 SWINE
    • 11.3.2.1 Growing incidence of infectious diseases to drive market
  • 11.3.3 POULTRY
    • 11.3.3.1 Increasing demand for poultry meat to contribute to market growth
  • 11.3.4 SHEEP & GOATS
    • 11.3.4.1 Growing global demand for wool to drive market
  • 11.3.5 OTHER LIVESTOCK ANIMALS

12 VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 MULTINATIONAL ANIMAL HEALTH COMPANIES
  • 12.2.1 INCREASED OUTSOURCING BY MULTINATIONAL ANIMAL HEALTH COMPANIES TO EXPAND GLOBAL PRODUCT DEVELOPMENT
• 12.3 MID-SIZED/SPECIALTY ANIMAL HEALTH FIRMS
  • 12.3.1 RISING RELIANCE OF MID-SIZED & SPECIALTY ANIMAL HEALTH FIRMS ON CDMO/CRO PARTNERS TO BOOST PIPELINES
• 12.4 START-UPS & VETERINARY BIOTECH FIRMS
  • 12.4.1 GROWING ENGAGEMENT OF START-UPS & VETERINARY BIOTECH FIRMS TO ACCESS ADVANCED DEVELOPMENT CAPABILITIES

13 VETERINARY CONTRACT MANUFACTURING & RESEARCH MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 13.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031
  • 13.2.3 NORTH AMERICA: VALUE ANALYSIS, 2024-2031
  • 13.2.4 US
    • 13.2.4.1 Rising pet population to drive demand
  • 13.2.5 CANADA
    • 13.2.5.1 Rising pet adoption rate to drive market
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 EUROPE: VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031
  • 13.3.3 EUROPE: VALUE ANALYSIS, 2024-2031
  • 13.3.4 GERMANY
    • 13.3.4.1 Germany to dominate European market during forecast period
  • 13.3.5 UK
    • 13.3.5.1 Increasing pet ownership to drive market growth
  • 13.3.6 FRANCE
    • 13.3.6.1 Rising cases of zoonotic diseases to drive market growth
  • 13.3.7 ITALY
    • 13.3.7.1 Growing livestock population to support market growth
  • 13.3.8 SPAIN
    • 13.3.8.1 Increasing animal healthcare expenditure to drive market growth
  • 13.3.9 NETHERLANDS
    • 13.3.9.1 Increasing companion animal population to drive market growth
  • 13.3.10 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031
  • 13.4.3 ASIA PACIFIC: VALUE ANALYSIS, 2024-2031
  • 13.4.4 CHINA
    • 13.4.4.1 China to dominate APAC market during forecast period
  • 13.4.5 JAPAN
    • 13.4.5.1 Aging pet population to drive market
  • 13.4.6 INDIA
    • 13.4.6.1 Rising livestock population to boost market growth
  • 13.4.7 AUSTRALIA
    • 13.4.7.1 Rising livestock animal population and increasing pet ownership to support market growth
  • 13.4.8 SOUTH KOREA
    • 13.4.8.1 Increasing demand for preventive care and aging pet population to drive market
  • 13.4.9 THAILAND
    • 13.4.9.1 Increasing demand for preventive care and aging pet population to drive market
  • 13.4.10 NEW ZEALAND
    • 13.4.10.1 High biosecurity standards to drive market
  • 13.4.11 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 LATIN AMERICA: VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031
  • 13.5.3 LATIN AMERICA: VALUE ANALYSIS, 2024-2031
  • 13.5.4 BRAZIL
    • 13.5.4.1 Brazil to dominate LATAM market due to rapidly increasing livestock population
  • 13.5.5 MEXICO
    • 13.5.5.1 Rising demand for animal-derived food products to contribute to market growth
  • 13.5.6 ARGENTINA
    • 13.5.6.1 Rising livestock population to fuel market growth
  • 13.5.7 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 13.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PRODUCT TYPE, 2024-2031
  • 13.6.3 MIDDLE EAST & AFRICA: VALUE ANALYSIS, 2024-2031
  • 13.6.4 GCC COUNTRIES
    • 13.6.4.1 Kingdom of Saudi Arabia (KSA)
      • 13.6.4.1.1 Technological advancements & government initiatives to boost growth
    • 13.6.4.2 United Arab Emirates (UAE)
      • 13.6.4.2.1 Government support and high livestock population to fuel UAE's market growth
    • 13.6.4.3 Rest of GCC Countries
  • 13.6.5 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 14.3 REVENUE ANALYSIS, 2021-2025
  • 14.3.1 KEY VETERINARY CONTRACT RESEARCH ORGANIZATIONS
  • 14.3.2 KEY VETERINARY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
• 14.4 VETERINARY CRO MARKET SHARE ANALYSIS, 2025
  • 14.4.1 GLOBAL MARKET SHARE ANALYSIS OF VETERINARY CONTRACT RESEARCH ORGANIZATIONS, 2025
  • 14.4.2 RANKING OF KEY MARKET PLAYERS
  • 14.4.3 US MARKET SHARE ANALYSIS OF VETERINARY CONTRACT RESEARCH ORGANIZATIONS, 2025
  • 14.4.4 EUROPE MARKET SHARE ANALYSIS OF VETERINARY CONTRACT RESEARCH ORGANIZATIONS, 2025
• 14.5 VETERINARY CDMO MARKET SHARE ANALYSIS, 2025
  • 14.5.1 GLOBAL MARKET SHARE ANALYSIS OF VETERINARY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, 2025
  • 14.5.2 RANKING OF KEY MARKET PLAYERS
  • 14.5.3 US MARKET SHARE ANALYSIS OF VETERINARY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, 2025
  • 14.5.4 EUROPE MARKET SHARE ANALYSIS OF VETERINARY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, 2025
• 14.6 COMPANY EVALUATION MATRIX: KEY VETERINARY CROS, 2025
  • 14.6.1 STARS
  • 14.6.2 EMERGING LEADERS
  • 14.6.3 PERVASIVE PLAYERS
  • 14.6.4 PARTICIPANTS
  • 14.6.5 COMPANY FOOTPRINT: KEY VETERINARY CROS, 2025
    • 14.6.5.1 Company footprint
    • 14.6.5.2 Region footprint
    • 14.6.5.3 Service footprint
    • 14.6.5.4 Product type footprint
    • 14.6.5.5 Animal type footprint
• 14.7 COMPANY EVALUATION MATRIX: VETERINARY CRO STARTUPS/SMES, 2025
  • 14.7.1 PROGRESSIVE COMPANIES
  • 14.7.2 RESPONSIVE COMPANIES
  • 14.7.3 DYNAMIC COMPANIES
  • 14.7.4 STARTING BLOCKS
  • 14.7.5 COMPETITIVE BENCHMARKING: VETERINARY CRO STARTUPS/SMES, 2025
    • 14.7.5.1 Detailed list of key veterinary CRO startups/SMEs
    • 14.7.5.2 Competitive benchmarking of key veterinary CRO startups/SMEs
• 14.8 COMPANY EVALUATION MATRIX: VETERINARY CDMOS, 2025
  • 14.8.1 STARS
  • 14.8.2 EMERGING LEADERS
  • 14.8.3 PERVASIVE PLAYERS
  • 14.8.4 PARTICIPANTS
  • 14.8.5 COMPANY FOOTPRINT: KEY VETERINARY CDMOS, 2025
    • 14.8.5.1 Company footprint
    • 14.8.5.2 Region footprint
    • 14.8.5.3 Service footprint
    • 14.8.5.4 Product type footprint
    • 14.8.5.5 Animal type footprint
• 14.9 COMPANY EVALUATION MATRIX: VETERINARY CDMO STARTUPS/SMES, 2025
  • 14.9.1 PROGRESSIVE COMPANIES
  • 14.9.2 RESPONSIVE COMPANIES
  • 14.9.3 DYNAMIC COMPANIES
  • 14.9.4 STARTING BLOCKS
  • 14.9.5 COMPETITIVE BENCHMARKING: VETERINARY CDMO STARTUPS/SMES, 2025
    • 14.9.5.1 Detailed list of key veterinary CDMO startups/SMEs
    • 14.9.5.2 Competitive benchmarking of key veterinary CDMO startups/SMEs
• 14.10 SERVICE COMPARATIVE ANALYSIS
• 14.11 COMPANY VALUATION & FINANCIAL METRICS
  • 14.11.1 FINANCIAL METRICS
  • 14.11.2 COMPANY VALUATION
• 14.12 COMPETITIVE SCENARIO
  • 14.12.1 SERVICE LAUNCHES & APPROVALS
  • 14.12.2 DEALS
  • 14.12.3 EXPANSIONS
  • 14.12.4 OTHER DEVELOPMENTS

15 COMPANY PROFILES

• 15.1 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
  • 15.1.1 KEY PLAYERS
    • 15.1.1.1 Argenta Holdco Limited
      • 15.1.1.1.1 Business overview
      • 15.1.1.1.2 Services offered
      • 15.1.1.1.3 Recent developments
        • 15.1.1.1.3.1 Service launches & upgrades
        • 15.1.1.1.3.2 Deals
        • 15.1.1.1.3.3 Expansions
      • 15.1.1.1.4 MnM view
        • 15.1.1.1.4.1 Key strengths
        • 15.1.1.1.4.2 Strategic choices
        • 15.1.1.1.4.3 Weaknesses & competitive threats
    • 15.1.1.2 Aenova Group
      • 15.1.1.2.1 Business overview
      • 15.1.1.2.2 Services offered
      • 15.1.1.2.3 Recent developments
        • 15.1.1.2.3.1 Expansions
        • 15.1.1.2.3.2 Other developments
      • 15.1.1.2.4 MnM view
        • 15.1.1.2.4.1 Key strengths
        • 15.1.1.2.4.2 Strategic choices
        • 15.1.1.2.4.3 Weaknesses & competitive threats
    • 15.1.1.3 FAREVA SA
      • 15.1.1.3.1 Business overview
      • 15.1.1.3.2 Services offered
      • 15.1.1.3.3 MnM view
        • 15.1.1.3.3.1 Key strengths
        • 15.1.1.3.3.2 Strategic choices
        • 15.1.1.3.3.3 Weaknesses & competitive threats
    • 15.1.1.4 Vetio
      • 15.1.1.4.1 Business overview
      • 15.1.1.4.2 Services offered
      • 15.1.1.4.3 MnM view
        • 15.1.1.4.3.1 Key strengths
        • 15.1.1.4.3.2 Strategic choices
        • 15.1.1.4.3.3 Weaknesses & competitive threats
    • 15.1.1.5 TriRx Pharmaceutical Services
      • 15.1.1.5.1 Business overview
      • 15.1.1.5.2 Services offered
      • 15.1.1.5.3 MnM view
        • 15.1.1.5.3.1 Key strengths
        • 15.1.1.5.3.2 Strategic choices
        • 15.1.1.5.3.3 Weaknesses & competitive threats
    • 15.1.1.6 Indian Immunologicals Ltd.
      • 15.1.1.6.1 Business overview
      • 15.1.1.6.2 Services offered
    • 15.1.1.7 Recipharm AB
      • 15.1.1.7.1 Business overview
      • 15.1.1.7.2 Services offered
      • 15.1.1.7.3 Recent developments
        • 15.1.1.7.3.1 Technology launches
        • 15.1.1.7.3.2 Deals
        • 15.1.1.7.3.3 Expansions
        • 15.1.1.7.3.4 Other developments
    • 15.1.1.8 LABIANA
      • 15.1.1.8.1 Business overview
      • 15.1.1.8.2 Services offered
      • 15.1.1.8.3 Recent developments
        • 15.1.1.8.3.1 Other developments
    • 15.1.1.9 Syngene International Limited
      • 15.1.1.9.1 Business overview
      • 15.1.1.9.2 Services offered
      • 15.1.1.9.3 Recent developments
        • 15.1.1.9.3.1 Deals
        • 15.1.1.9.3.2 Other developments
    • 15.1.1.10 CZ Vaccines
      • 15.1.1.10.1 Business overview
      • 15.1.1.10.2 Services offered
  • 15.1.2 OTHER PLAYERS
    • 15.1.2.1 AB7 Group
    • 15.1.2.2 Kela Health
    • 15.1.2.3 Eirgen Pharma
    • 15.1.2.4 Bioingenium
    • 15.1.2.5 Elise Biopharma
• 15.2 CONTRACT RESEARCH ORGANIZATIONS
  • 15.2.1 KEY PLAYERS
    • 15.2.1.1 Labcorp
      • 15.2.1.1.1 Business overview
      • 15.2.1.1.2 Services offered
      • 15.2.1.1.3 Recent developments
        • 15.2.1.1.3.1 Technology launches
        • 15.2.1.1.3.2 Expansions
      • 15.2.1.1.4 MnM view
        • 15.2.1.1.4.1 Key strengths
        • 15.2.1.1.4.2 Strategic choices
        • 15.2.1.1.4.3 Weaknesses & competitive threats
    • 15.2.1.2 Eurofins Scientific
      • 15.2.1.2.1 Business overview
      • 15.2.1.2.2 Services offered
      • 15.2.1.2.3 Recent developments
        • 15.2.1.2.3.1 Deals
      • 15.2.1.2.4 MnM view
        • 15.2.1.2.4.1 Key strengths
        • 15.2.1.2.4.2 Strategic choices
        • 15.2.1.2.4.3 Weaknesses & competitive threats
    • 15.2.1.3 Charles River Laboratories
      • 15.2.1.3.1 Business overview
      • 15.2.1.3.2 Services offered
      • 15.2.1.3.3 MnM view
        • 15.2.1.3.3.1 Key strengths
        • 15.2.1.3.3.2 Strategic choices
        • 15.2.1.3.3.3 Weaknesses & competitive threats
    • 15.2.1.4 Knoell Germany GmbH
      • 15.2.1.4.1 Business overview
      • 15.2.1.4.2 Services offered
      • 15.2.1.4.3 Recent developments
        • 15.2.1.4.3.1 Deals
      • 15.2.1.4.4 Other developments
      • 15.2.1.4.5 MnM view
        • 15.2.1.4.5.1 Key strengths
        • 15.2.1.4.5.2 Strategic choices
        • 15.2.1.4.5.3 Weaknesses & competitive threats
    • 15.2.1.5 Evotec
      • 15.2.1.5.1 Business overview
      • 15.2.1.5.2 Services offered
        • 15.2.1.5.2.1 Deals
      • 15.2.1.5.3 MnM view
        • 15.2.1.5.3.1 Key strengths
        • 15.2.1.5.3.2 Strategic choices
        • 15.2.1.5.3.3 Weaknesses & competitive threats
    • 15.2.1.6 KLIFOVET GmbH
      • 15.2.1.6.1 Business overview
      • 15.2.1.6.2 Services offered
    • 15.2.1.7 Clinglobal
      • 15.2.1.7.1 Business overview
      • 15.2.1.7.2 Services offered
      • 15.2.1.7.3 Recent developments
        • 15.2.1.7.3.1 Service launches
        • 15.2.1.7.3.2 Deals
        • 15.2.1.7.3.3 Other developments
    • 15.2.1.8 BioAgile Therapeutics Private Limited
      • 15.2.1.8.1 Business overview
      • 15.2.1.8.2 Services offered
    • 15.2.1.9 Vetspin SRL
      • 15.2.1.9.1 Business overview
      • 15.2.1.9.2 Services offered
    • 15.2.1.10 Veterinary Research Management
      • 15.2.1.10.1 Business overview
      • 15.2.1.10.2 Services offered
  • 15.2.2 OTHER PLAYERS
    • 15.2.2.1 Ridgeway Research Ltd.
    • 15.2.2.2 Lohlein and Wolf Vet Research
    • 15.2.2.3 Cebiphar
    • 15.2.2.4 OCRvet
    • 15.2.2.5 East Tennessee Clinical Research, Inc.

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
• 16.2 RESEARCH METHODOLOGY DESIGN
  • 16.2.1 SECONDARY DATA
    • 16.2.1.1 Key data from secondary sources
  • 16.2.2 PRIMARY DATA
    • 16.2.2.1 Key data from primary sources
    • 16.2.2.2 Key industry insights
• 16.3 MARKET SIZE ESTIMATION
  • 16.3.1 BOTTOM-UP APPROACH
• 16.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 16.5 MARKET SHARE ESTIMATION
  • 16.5.1 RESEARCH ASSUMPTIONS
  • 16.5.2 GROWTH RATE ASSUMPTIONS
• 16.6 RISK ASSESSMENT
• 16.7 RESEARCH LIMITATIONS
  • 16.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 16.7.2 SCOPE-RELATED LIMITATIONS

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
  • 17.3.1 SERVICE ANALYSIS
  • 17.3.2 COMPANY INFORMATION
  • 17.3.3 GEOGRAPHIC ANALYSIS
  • 17.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
  • 17.3.5 COUNTRY-LEVEL VOLUME ANALYSIS, BY PRODUCT TYPE
  • 17.3.6 MARKET SHARE ANALYSIS, BY SERVICE (TOP 5 PLAYERS)
  • 17.3.7 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS